MOLNZ Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF3.29 |
| 52 Week High | CHF6.17 |
| 52 Week Low | CHF3.10 |
| Beta | 0.80 |
| 1 Month Change | 0.30% |
| 3 Month Change | -14.43% |
| 1 Year Change | -44.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| MOLNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.6% | 1.9% | 0.5% |
| 1Y | -45.0% | -20.4% | 6.3% |
Return vs Industry: MOLNZ underperformed the UK Biotechs industry which returned -20.4% over the past year.
Return vs Market: MOLNZ underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| MOLNZ volatility | |
|---|---|
| MOLNZ Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: MOLNZ has not had significant price volatility in the past 3 months.
Volatility Over Time: MOLNZ's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 168 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| MOLNZ fundamental statistics | |
|---|---|
| Market cap | CHF109.67m |
| Earnings (TTM) | -CHF58.53m |
| Revenue (TTM) | CHF6.73m |
16.3x
P/S Ratio-1.9x
P/E RatioIs MOLNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLNZ income statement (TTM) | |
|---|---|
| Revenue | CHF6.73m |
| Cost of Revenue | CHF47.84m |
| Gross Profit | -CHF41.12m |
| Other Expenses | CHF17.41m |
| Earnings | -CHF58.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 26, 2024
| Earnings per share (EPS) | -1.76 |
| Gross Margin | -611.33% |
| Net Profit Margin | -870.22% |
| Debt/Equity Ratio | 0% |
How did MOLNZ perform over the long term?
See historical performance and comparison